Burning Rock Biotech Limited (NASDAQ:BNR) Short Interest Down 6.6% in January

Burning Rock Biotech Limited (NASDAQ:BNR) was the recipient of a large decline in short interest in January. As of January 15th, there was short interest totalling 60,500 shares, a decline of 6.6% from the December 31st total of 64,800 shares. Based on an average daily volume of 26,300 shares, the short-interest ratio is presently 2.3 days. Approximately 0.7% of the company’s shares are sold short.

Burning Rock Biotech Price Performance

Shares of BNR stock traded down $0.05 on Monday, hitting $6.64. The company’s stock had a trading volume of 6,883 shares, compared to its average volume of 5,278. The stock has a market capitalization of $67.97 million, a price-to-earnings ratio of -2.21 and a beta of 0.55. Burning Rock Biotech has a fifty-two week low of $2.62 and a fifty-two week high of $8.99. The firm’s fifty day moving average price is $6.66 and its 200-day moving average price is $5.32.

Burning Rock Biotech (NASDAQ:BNR) last posted its quarterly earnings data on Tuesday, December 3rd. The company reported ($0.50) earnings per share (EPS) for the quarter. Burning Rock Biotech had a negative return on equity of 60.68% and a negative net margin of 83.50%.

Burning Rock Biotech Company Profile

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.